U.S. Markets open in 6 hrs 55 mins
  • S&P Futures

    4,116.50
    -8.00 (-0.19%)
     
  • Dow Futures

    32,701.00
    -36.00 (-0.11%)
     
  • Nasdaq Futures

    12,987.25
    -44.25 (-0.34%)
     
  • Russell 2000 Futures

    1,910.00
    -4.60 (-0.24%)
     
  • Crude Oil

    89.55
    -0.95 (-1.05%)
     
  • Gold

    1,792.40
    -1.60 (-0.09%)
     
  • Silver

    20.35
    -0.13 (-0.62%)
     
  • EUR/USD

    1.0210
    -0.0007 (-0.0715%)
     
  • 10-Yr Bond

    2.7970
    0.0000 (0.00%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2072
    -0.0004 (-0.0350%)
     
  • USD/JPY

    135.0370
    -0.0790 (-0.0585%)
     
  • BTC-USD

    22,893.89
    -894.58 (-3.76%)
     
  • CMC Crypto 200

    531.61
    -25.74 (-4.62%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,819.33
    -180.67 (-0.65%)
     

Industry Analysts Just Upgraded Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Revenue Forecasts By 10%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

G1 Therapeutics, Inc. (NASDAQ:GTHX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased their revenue numbers, with a view that G1 Therapeutics will make substantially more sales than they'd previously expected.

Following the upgrade, the latest consensus from G1 Therapeutics' seven analysts is for revenues of US$46m in 2022, which would reflect a substantial 92% improvement in sales compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$3.82. Yet before this consensus update, the analysts had been forecasting revenues of US$42m and losses of US$3.85 per share in 2022. So there's been quite a change-up of views after the recent consensus updates, withthe analysts noticeably increasing their revenue forecasts while also expecting losses per share to hold steady.

Check out our latest analysis for G1 Therapeutics

earnings-and-revenue-growth
earnings-and-revenue-growth

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting G1 Therapeutics' growth to accelerate, with the forecast 138% annualised growth to the end of 2022 ranking favourably alongside historical growth of 74% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 14% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that G1 Therapeutics is expected to grow much faster than its industry.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting G1 Therapeutics is moving incrementally towards profitability. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at G1 Therapeutics.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple G1 Therapeutics analysts - going out to 2024, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here